Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

BIOA


Fundamental

Company: BioAge Labs Inc
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -2.24
Insider Own: 41.29%
Shs Outstand: 35.85M
Perf Week: 5.08%
Market Cap: 163.12M
Forward P/E: -
EPS next Y: -2.51
Insider Trans: 0.02%
Shs Float: 21.05M
Perf Month: -5.21%
Enterprise Value: -125.43M
PEG: -
EPS next Q: -0.58
Inst Own: 33.12%
Short Float: 11.33%
Perf Quarter: 19.11%
Income: -79.03M
P/S: 42.26
EPS this Y: 66.87%
Inst Trans: 5.45%
Short Ratio: 10.14
Perf Half Y: 0.66%
Sales: 3.86M
P/B: 0.55
EPS next Y Percentage: -14.08%
ROA: -32.48%
Short Interest: 2.39M
Perf YTD: -21.42%
Book/sh: 8.22
P/C: 0.55
EPS next 5Y: 26.87%
ROE: -35.88%
52W High: 26.62 -82.91%
Perf Year: -
Cash/sh: 8.29
P/FCF: -
EPS past 3/5Y: -30.62% -
ROIC: -26.58%
52W Low: 2.88 57.99%
Perf 3Y: -
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: 95.34%
Volatility W: 3.11%
Volatility M: 4.07%
Perf 5Y: -
Dividend TTM: -
EV/Sales: -32.49
EPS Y/Y TTM: -
Oper. Margin: -2364.20%
ATR (14): 0.18
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 13.21
Sales Y/Y TTM: -
Profit Margin: -2045.74%
RSI (14): 53.99
Recom: 3.50
Dividend Gr. 3/5Y: - -
Current Ratio: 13.21
EPS Q/Q: -51.32%
SMA20: 1.44%
Beta: -
Target Price: 4.67
Payout: -
Debt/Eq: 0.03
Sales Q/Q: -
SMA50: 2.35%
Rel Volume: 0.84
Prev Close: 4.46
Employees: 64
LT Debt/Eq: 0.01
Earnings: Aug 06 AMC
SMA200: -32.52%
Avg Volume: 235.31K
Price: 4.55
IPO: Sep 26, 2024
Option/Short: Yes / Yes
EPS/Sales Surpr.: -24.56% -
Trades:
Volume: 197,283
Change: 2.02%

Technical:


Latest News:

Eli Lilly partner BioAge seeks up to $587 mln valuation in US IPO - XM somewhat bullish
BIOA

Summary: Obesity drug developer BioAge seeking up to $587 million valuation in US IPO, healthcare firms performing well in subdued US IPO market in 2024, BioAge's azelaprag is a GLP-1 agonist like Zepbound and Wegovy

Full article
2024-09-18T20:27:46Z
Thermo Fisher Scientific Adds New Bioanalytical Lab In Sweden - Contract Pharma neutral
TMO

Summary: Thermo Fisher Scientific's PPD clinical research business is expanding its global laboratory services with a new bioanalytical lab in Gothenburg, Sweden, adjacent to AstraZeneca's research site. The new lab will offer advanced technologies and methodologies to support pharmaceutical and biotech customers across all phases of drug development.

Full article
2024-09-18T16:02:02Z
Bioacoustics Sensing System Market to See Incredible Growth 2024-2031 |AT&T, IBM, Honeywell neutral
ATT IBM SSNLF

Summary: The press release discusses the Bioacoustics Sensing System market segmentation, business strategies, and key players such as AT&T, IBM, and Samsung Electronics. It also emphasizes the importance of understanding competitor financials and potential partnerships for business growth.

Full article
2024-04-28T05:11:36Z